BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 12/08/2026

National Cancer Institute Seeks License for CRISPR Engineered Cancer Cell Line to Study Immunotherapy Strategies

The National Cancer Institute is seeking licensees for a CRISPR/Cas9-engineered MC38 B2m knockout murine colon cancer cell line, which models tumor resistance to PD-1/PD-L1 checkpoint blockade, to study alternative or combination immunotherapy strategies for cancers that evade conventional T-cell recognition.

Source: Federal Register — Health and Human ServicesOpen original release →